Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Purpose: Epidermal growth factor receptor (EGFR) signal transduction pathways are implicated in malignant glioma aggressiveness and promote tumor cell invasion, proliferation, and angiogenesis. Nevertheless, response to EGFR tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) has been disappointing in clinical trials. One potential explanation may come from the diversity of molecular alterations seen in gliomas. To validate that hypothesis, we have investigated responses to gefitinib on various tumor parameters in human malignant gliomas that exhibited different molecular alterations. Experimental Design: We used a panel of six human malignant gliomas from established xenografts characterized for their genetic (EGFR, PTEN, TP53, and CDKN2A) and molecular (EGFR, PTEN, ERK, and Akt) alterations. Tumors were treated with gefitinib (1 or 10 μmol/L) for prolonged periods (8 or 16 days) in an organotypic brain slice model that allowed quantification of invasion, proliferation, and angiogenesis. Results: In nontreated tumors, EGFR amplification was associated with profuse tumor cell invasion. After treatment, invasion was inhibited in tumors with EGFR amplification in a dose-dependent manner. Treatment had only antiproliferative effect in two of three tumors with EGFR amplification. Tumors with PTEN loss were resistant to treatment. We did not observe shrinkage of the tumors after treatment. None of the tumors had mutations of the EGFR kinase domain. Gefitinib had similar antiangiogenic effect in all of the tumors. Conclusions: Gefitinib reduces cell invasion in EGFR amplified tumors. PTEN loss of expression seems to be a determinant of resistance. Interestingly, inhibition of angiogenesis by gefitinib seems independent on the EGFR genetic status of the tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., Kaye, S. B., Gianni, L., Harris, A., Bjork, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.100 · Cited by 829
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Rich, J. N., Reardon, D. A., Peery, T., Dowell, J. M., Quinn, J. A., Penne, K. L., Wikstrand, C. J., Van Duyn, L. B., Dancey, J. E., McLendon, R. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.110 · Cited by 734
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas
Chakravarti, A., Zhai, G., Suzuki, Y., Sarkesh, S., Black, P. M., Muzikansky, A., & Loeffler, J. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.193 · Cited by 377
Cited by
Zhou, X., Ren, Y., Moore, L., Mei, M., You, Y., Xu, P., Wang, B., Wang, G., Jia, Z., Pu, P., et al. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2009.126 · Cited by 358
miR-21 improves the neurological outcome after traumatic brain injury in rats
Ge, X.-T., Lei, P., Wang, H.-C., Zhang, A.-L., Han, Z.-L., Chen, X., Li, S.-H., Jiang, R.-C., Kang, C.-S., & Zhang, J.-N. (2014) · Scientific Reports · doi:10.1038/srep06718 · Cited by 167
The role of MiRNA-21 in gliomas: Hope for a novel therapeutic intervention?
Aloizou, A.-M., Pateraki, G., Siokas, V., Mentis, A.-F. A., Liampas, I., Lazopoulos, G., Kovatsi, L., Mitsias, P. D., Bogdanos, D. P., Paterakis, K., et al. (2020) · Toxicology Reports · doi:10.1016/j.toxrep.2020.11.001 · Cited by 69
Schlienger, S., Campbell, S., Pasquin, S., Gaboury, L., & Claing, A. (2016) · Oncotarget · doi:10.18632/oncotarget.7515 · Cited by 26
“For example, expression of the Epidermal Growth Factor Receptor (EGFR) is increased in more than 50% of TNBC and is associated with proliferation and invasion engaging mitogenic and survival pathways [1-3].”
BackgroundTamiya, M., Kunimasa, K., Nishino, K., Matsumoto, S., Kawachi, H., Kuno, K., Inoue, T., Kuhara, H., Imamura, F., Goto, K., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-020-00966-7 · Cited by 5
Metadata
- Authors
- Guillamo, J.-S., de Boüard, S., Valable, S., Marteau, L., Leuraud, P., Marie, Y., Poupon, M.-F., Parienti, J.-J., Raymond, E., & Peschanski, M.
- Venue
- Clinical Cancer Research
- Published
- 2009-06-01
- Volume
- 15
- Issue
- 11
- Pages
- 3697-3704
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2106862355
- Cited by
- 72
- References
- 5
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-08-2042
- The paper
- Guillamo, J.-S., de Boüard, S., Valable, S., Marteau, L., Leuraud, P., Marie, Y., Poupon, M.-F., Parienti, J.-J., Raymond, E., & Peschanski, M. (2009). Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-08-2042
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.